47 results on '"Blomqvist C."'
Search Results
2. Risk of coronary stenosis after adjuvant radiotherapy for breast cancer
3. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
4. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
5. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.
6. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
7. Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients
8. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
9. Nuclear osteopontin-c is a prognostic breast cancer marker
10. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
11. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation
12. Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial
13. High cyclin B1 expression is associated with poor survival in breast cancer
14. Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke
15. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
16. Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides
17. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
18. Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone—A Histomorphometric Study
19. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer
20. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids
21. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
22. Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
23. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
24. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas
25. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
26. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
27. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
28. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
29. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
30. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma
31. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence
32. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer
33. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients
34. Breast cancer risk estimation in families with history of breast cancer
35. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
36. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization
37. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens
38. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
39. Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas
40. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma
41. Type I and type III collagen metabolites in adult osteosarcoma patients
42. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
43. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma
44. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma
45. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial
46. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
47. Multicentre evaluation of a direct coagglutination test for group A streptococci
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.